PROSPERO International prospective register of systematic reviews

Transcription

1 PROSPERO International prospective register of systematic reviews Follow-up care for survivors of lymphoma who have received curative-intent treatment Jonathan Sussman, Norma Varela, Matthew Cheung, Graeme Fraser, Lisa Hicks, Laura Jimenez-Juan, Danny Kraftcheck, Angela Boudreau, Shawn Sajkowski, Robin McQuillan, Jonathan Mandel Citation Jonathan Sussman, Norma Varela, Matthew Cheung, Graeme Fraser, Lisa Hicks, Laura Jimenez-Juan, Danny Kraftcheck, Angela Boudreau, Shawn Sajkowski, Robin McQuillan, Jonathan Mandel. Follow-up care for survivors of lymphoma who have received curative-intent treatment. PROSPERO 2015:CRD Available from Review question(s) What surveillance clinical activities have been shown to be effective at detecting clinical recurrence or further primary lymphoma in asymptomatic survivors who have received curative-intent treatment? What is the appropriate frequency and timing for the surveillance of clinical activities that have been shown to be effective at detecting clinical recurrence or further primary lymphoma in asymptomatic survivors who have received curative-intent treatment? What surveillance activities have been shown to be effective at detecting therapy-related malignancies (breast, lung cancer, other?) following treatment for Lymphoma in asymptomatic survivors who have received curative-intent treatment? Searches 1. Inventory of Cancer Guidelines (SAGE) 2. National Guideline Clearing House 3. CMAJ Infobase 4. Cochrane Database of Systematic Reviews 5. MEDLINE(OVID) 6. EMBASE (OVID) Studies were excluded if they were: 1. Abstracts, letters, case reports, comments, books, notes, or editorial publication types 2. Articles published in a language other than English because resources were not available for translation services Link to search strategy Types of study to be included Practice guidelines Systematic reviews with or without meta-analysis Randomized Phase II and III Trials Page: 1 / 5

2 Other comparative studies If single arm studies included, sample size should be greater than 100. Condition or domain being studied Type of blood cancer that develop in the lymphatic system. The two main types of lymphoma are Hodgkin lymphoma (HL) which is the most curable form of cancer, and non-hodgkin lymphoma (NHL). NHL can act as slow- or fastgrowing cancer. While fast-growing NHL can be cured, treatment for patients with low-grow NHL, may last for many years. According to the National Cancer Institute, approximately 2.1% of men and women will be diagnosed with non- Hodgkin lymphoma at some point during their lifetime, based on data ( Participants/ population Lymphoma survivors who have received curative-intent treatment Intervention(s), exposure(s) Clinical follow-up (medical history and physical examination) Laboratory Investigation Imaging Investigation Less intense vs more intense frequency for follow-up Surveillance for breast and lung cancer Comparator(s)/ control Do not anticipate comparative studies Context Inclusion Criteria: Articles identified in this literature search were eligible for inclusion if they met the following criteria: 1. Primary studies evaluating the the follow-up care for adult and/or adolescent survivors of lymphoma who have received curative-intent treatment. 2. Published full-report articles of randomized or nonrandomized studies with an appropriate control group, decision model studies, and single-arm studies with a sample size of at least 100 patients. 3. Studies reporting the outcomes of interest such as recurrence/relapse rate, overall survival rate, and relapse-free survival rate. Exclusion Criteria: Studies were excluded if they were: 1. Abstracts, letters, case reports, comments, books, notes, or editorial-type Page: 2 / 5

3 publications. Evidence Summary April 12, 2016 Page 4 2. Articles published in a language other than English because resources were not available for translation services. 3. Single-arm studies with a sample size <100 patients. Outcome(s) Primary outcomes Relapse rate, time to relapse, method of relapse detection and detection rate by follow-up activity. Secondary outcomes N/A Data extraction, (selection and coding) Single reviewer will extract the data with subsequent independent data audit Risk of bias (quality) assessment Risk of bias: no specific tool used Quality assessment: According to study design (e.g. AMSTAR, AGREE II, Information assessment, others) Strategy for data synthesis Descriptive data analysis due to the lack of evidence in this subject. Analysis of subgroups or subsets None Dissemination plans PEBC Reports - CCO Website, Current Oncology Journal Contact details for further information Ms Varela McMaster University - Juravinski Hospital G Wing 2nd Floor 711 Concession Street Hamilton, ON L8V 1C3 varela@mcmaster.ca Organisational affiliation of the review Program in Evidence-based Care Review team Dr Jonathan Sussman, Juravinski Cancer Centre Page: 3 / 5

4 Dr Norma Varela, PEBC Dr Matthew Cheung, Sunnybrook Health Science Centre Dr Graeme Fraser, Juravinski Cancer Centre Dr Lisa Hicks, St. Michael's Hospital Dr Laura Jimenez-Juan, Sunnybrook Health Sciences Centre Department of Medical Imaging Dr Danny Kraftcheck, Cancer Care Ontario Ms Angela Boudreau, Odette Cancer Care, Sunnybrook Health Science Centre Mr Shawn Sajkowski, Cancer Care Ontario Patient and Family Advisor Ms Robin McQuillan, Cancer Care Ontario Patient and Family Advisor Dr Jonathan Mandel, Oakville Trafalgar Memorial Hospital Anticipated or actual start date 15 July 2015 Anticipated completion date 12 April 2017 Funding sources/sponsors The PEBC is supported by the Ontario MOHLTC through CCO. All work produced by the PEBC is editorially independent from its funding source. Conflicts of interest Nine authors declared no conflicts of interest, and two (JM, LH) declared conflicts. JM reported a potential conflict because if lymphoma imaging indications were to become more liberal, his income as radiologist could potentially increase by more than $10,000. JM also declared that he had received $5,000 or more in a single year, plus other research support from SIEMENS, and he had been principal investigator for a clinical trial involving PET/MR studies. LH declared that she had been a co-principal investigator on a CIHR-industry grant from Gilead Sciences. The COIs declared above did not disqualify any individuals from performing their designated role in the development of this evidence summary, in accordance with the PEBC COI policy. Language English Country Canada Subject index terms status Subject indexing assigned by CRD Subject index terms Follow-Up Studies; Humans; Intention; Lymphoma; Survivors Stage of review Completed and published Date of registration in PROSPERO 18 June 2015 Date of publication of this revision 13 May 2016 Details of final report/publication(s) Sussman J, Varela N, Cheung M, Hicks L, Kraftcheck D, Mandel J, et al. Follow-up care for survivors of lymphoma who have received curative-intent treatment. Toronto (ON): Cancer Care Ontario; 2016 April 12. Program in Evidence- Page: 4 / 5

5 Powered by TCPDF ( Based Care Evidence Summary No.: DOI /CRD Stage of review at time of this submission Started Completed Preliminary searches Yes Yes Piloting of the study selection process Yes Yes Formal screening of search results against eligibility criteria Yes Yes Data extraction Yes Yes Risk of bias (quality) assessment Yes Yes Data analysis Yes Yes PROSPERO International prospective register of systematic reviews The information in this record has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Page: 5 / 5